The role of ACEIs/ARBs in COVID-19: Friend or foe?

Med Hypotheses. 2020 Sep:142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.

Authors

Zhe Zhou¹, Yumin Qiu¹, Jun Tao²

Affiliations

¹ Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
² Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Electronic address: [email protected].

No abstract available

Publication types

Letter

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin Receptor Antagonists / pharmacology*
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / enzymology
Coronavirus Infections / etiology
Disease Susceptibility
Humans
Models, Biological
Pandemics
Peptidyl-Dipeptidase A / metabolism
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / enzymology
Pneumonia, Viral / etiology
Research Design
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2